Alpine Global Management’s Viking Therapeutics VKTX Stock Holding History

Alpine Global Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,775	Closed	-$123K	–	721
2021 Q4	$123K	Buy	+26,775	New	+$150K	0.02%	612
2019 Q4	–	Sell	-25,000	Closed	-$172K	–	447
2019 Q3	$172K	Hold	25,000	–	–	0.04%	69
2019 Q2	$208K	Hold	25,000	–	–	0.06%	56
2019 Q1	$249K	Hold	25,000	–	–	0.07%	65
2018 Q4	$191K	Hold	25,000	–	–	0.05%	183
2018 Q3	$436K	Buy	+25,000	New	+$298K	0.08%	52
2018 Q2	–	Sell	-40,000	Closed	-$175K	–	111
2018 Q1	$175K	Hold	40,000	–	–	0.04%	89
2017 Q4	$162K	Buy	+40,000	New	+$116K	0.04%	138

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Alpine Global Management's VKTX Position: Q1 2022 in Review

Alpine Global Management sold out of Viking Therapeutics (VKTX) in Q1 2022, closing a stake of 26,775 shares — an estimated $123K sold.

Alpine Global Management first reported a position in VKTX in Q4 2017 and held it in 8 quarters. The position peaked at $436K in Q3 2018. 140 funds tracked by Wall St. Rank hold VKTX as of Q1 2022.

Alpine Global Management reported no remaining Viking Therapeutics position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 26,775 Viking Therapeutics shares in Q1 2022, an estimated $123K.
Alpine Global Management first reported a position in Viking Therapeutics in Q4 2017 and held it in 8 quarters.
Alpine Global Management's Viking Therapeutics position peaked at $436K in Q3 2018.
140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.